| Literature DB >> 29254154 |
Ze-Wu Meng1,2, Wei Pan1,2, Hai-Jie Hong1,2, Jiang-Zhi Chen1,2, Yan-Ling Chen1,2.
Abstract
The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is undefined among the different macroscopic types. This study evaluated the viability of the American Joint Committee on Cancer (AJCC) 8th edition staging classification for different macroscopic types. Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, we enrolled a total of 2,679 eligible patients with an estimated 199 periductal infiltrating type of ICC (ICC-PI) patients and 2,480 mass-forming type of ICC (ICC-MF) patients. After conducting a multivariate Cox analysis, we found that the AJCC 8th edition staging system was suitable for ICC-MF patients but not for ICC-PI patients according to cancer-specific survival (CSS) and overall survival (OS). The main reason was the similar hazard ratio (HR) between the ICC-PI patients with stage I and stage II disease according to CSS (HR:0.969, P = 0.949) and OS (HR:0.832, P = 0.703). Moreover, we found that ICC-PI patients in AJCC stage I had a similar HR as ICC-MF patients in AJCC stage II according to CSS (HR: 1.208, P = 0.475) and OS (HR:1.206, P = 0.456). Therefore, we suggested that ICC-PI patients may be defined as T2, which is classified as stage II disease. This suggestion for the AJCC 8th edition staging system would be more suitable for different macroscopic types of ICC but requires further verification in prospective clinical trials.Entities:
Keywords: TNM classification; clinicopathological characteristics; intrahepatic cholangiocarcinoma; macroscopic type; prognosis
Year: 2017 PMID: 29254154 PMCID: PMC5731864 DOI: 10.18632/oncotarget.20932
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Different AJCC staging definitions for intrahepatic cholangiocarcinoma based on the AJCC 6th edition (2004), AJCC 7th edition (2010) and AJCC 8th edition (2017) staging systems
| T1 | Single tumor without vascular invasion | T1 | Solitary tumor without vascular invasion | |||||||||||||
| T2 | Single tumor with vascular invasion or multiple tumors none more than 5 cm | T2a | Solitary tumor with vascular invasion | |||||||||||||
| T2b | Multiple tumors, with or without vascular invasion | |||||||||||||||
| T3 | Multiple tumors more than 5 cm or tumors involving major branch of portal or hepatic veins | T3 | Tumor perforating the visceral peritoneum or involving the local extra hepatic structures by direct invasion | |||||||||||||
| T4 | Tumors with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum | T4 | Tumor with periductal invasion | |||||||||||||
| N0 | No regional lymph node metastasis | N0 | No regional lymph node metastasis | |||||||||||||
| N1 | Regional lymph node metastasis | N1 | Regional lymph node metastasis present | |||||||||||||
| M0 | No distant metastasis | M0 | No distant metastasis | |||||||||||||
| M1 | Distant metastasis | M1 | Distant metastasis | |||||||||||||
| T1a | Solitary tumor ≤ 5 cm without vascular invasion | |||||||||||||||
| T1b | Solitary tumor > 5 cm without vascular invasion | |||||||||||||||
| T2 | Solitary tumor with intrahepatic vascular invasion or multiple tumors, with or without vascular invasion | |||||||||||||||
| T3 | Tumor perforating the visceral peritoneum | |||||||||||||||
| T4 | Tumor involving the local extrahepatic structures by direct invasion | |||||||||||||||
| N0 | No regional lymph node metastasis | |||||||||||||||
| N1 | Regional lymph node metastasis present | |||||||||||||||
| M0 | No distant metastasis | |||||||||||||||
| M1 | Distant metastasis present | |||||||||||||||
| I | T1 | N0 | M0 | I | T1 | N0 | M0 | I a | T1a | N0 | M0 | |||||
| II | T2 | N0 | M0 | II | T2a | N0 | M0 | I b | T1b | N0 | M0 | |||||
| III a | T3 | N0 | M0 | T2b | N0 | M0 | II | T2 | N0 | M0 | ||||||
| III b | T4 | N0 | M0 | III | T3 | N0 | M0 | III a | T3 | N0 | M0 | |||||
| III c | Any T | N1 | M0 | IVa | T4 | N0 | M0 | III b | T4 | N0 | M0 | |||||
| IV | Any T | Any N | M1 | Any T | N1 | M0 | Any T | N1 | M0 | |||||||
| IVb | Any T | Any N | M1 | IV | Any T | Any N | M1 | |||||||||
Abbreviations: AJCC, American Joint Committee on Cancer.
Clinicopathological characteristics of patients with the MF-type and PI-type of intrahepatic cholangiocarcinoma
| Characteristic | MF-type ( | PI-type ( | Total ( | Pa |
|---|---|---|---|---|
| No (%) | No (%) | No (%) | ||
| Age (years) | 0.878 | |||
| ≤ 60 | 753 (30.4) | 62 (31.2) | 815 (30.4) | |
| > 60 | 1727 (69.6) | 137 (68.8) | 1864 (69.6) | |
| Race | ||||
| White | 1942 (78.3) | 149 (74.9) | 2091 (78.1) | |
| Black | 190 (7.7) | 28 (14.1) | 218 (8.1) | |
| Otherb | 348 (14.0) | 22 (11.0) | 370 (13.8) | |
| Sex | 0.878 | |||
| Male | 1425 (57.5) | 116 (58.3) | 1541 (57.5) | |
| Female | 1055 (42.5) | 83 (41.7) | 1138 (42.5) | |
| Marital status | 0.350 | |||
| Married | 1442 (58.1) | 123 (61.8) | 1565 (58.4) | |
| Not marriedc | 1038 (41.9) | 76 (38.2) | 1114 (41.6) | |
| Histologic grade | 0.152 | |||
| Grade I | 123 (5.0) | 4 (2.0) | 127 (4.7) | |
| Grade II | 517 (20.8) | 52 (26.1) | 569 (21.2) | |
| Grade III | 463 (18.7) | 38 (19.1) | 501 (18.7) | |
| Grade IV | 9 (0.4) | 1 (0.5) | 10 (0.5) | |
| Unknown | 1368 (55.1) | 104 (52.3) | 1472 (54.9) | |
| AJCC stage (8th edition, 2017) | ||||
| Stage I | 597 (24.1) | 48 (24.1) | 645 (24.1) | |
| Stage II | 533 (21.5) | 28 (14.1) | 561 (20.9) | |
| Stage III | 498 (20.1) | 40 (20.1) | 538 (20.1) | |
| Stage IV | 852 (34.3) | 83 (41.7) | 935 (34.9) | |
| Node stage | 0.979 | |||
| N0 | 1677 (67.6) | 133 (66.8) | 1810 (67.6) | |
| N1 | 706 (28.5) | 57 (28.7) | 763 (28.5) | |
| NX | 97 (3.9) | 9 (4.5) | 106 (3.9) | |
| Surgery performed | ||||
| Yes | 652 (26.3) | 67 (33.7) | 719 (26.8) | |
| No | 1828 (73.7) | 132 (66.3) | 1960 (73.2) |
Abbreviations: AJCC, American Joint Committee on Cancer. MF, mass-forming; PI, periductal infiltrating; NX: Regional lymph nodes could not be assessed.
aBold type indicates statistical significance.
bOther includes Asian/Pacific Islander and American Indian/Alaskan native.
cNot married includes single, divorced, separated, unmarried or domestic partner, and widowed.
Figure 1Kaplan–Meier curves of cancer-specific survival (CSS, A) and overall survival (OS, B) for the mass-forming type (MF-type) vs. periductal infiltrating type (PI-type) of intrahepatic cholangiocarcinoma.
Multivariate Cox analysis of cancer-specific survival and overall survival for the different growth patterns of intrahepatic cholangiocarcinoma
| Characteristic | Cancer-specific survival | Overall survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MF-type | PI-type | PI-type | ||||||||||
| HR | 95% CI | pa | HR | 95% CI | pa | HR | 95% CI | pa | HR | 95% CI | pa | |
| Age (years) | ||||||||||||
| ≤ 60 | 1 | 1 | 1 | 1 | ||||||||
| > 60 | 1.505 | 1.260–1.798 | 1.888 | 1.029–3.463 | 1.543 | 1.299–1.834 | 2.058 | 1.127–3.757 | ||||
| Race | ||||||||||||
| White | 1 | 1 | 1 | 1 | ||||||||
| Black | 1.243 | 0.913–1.691 | 0.168 | 1.078 | 0.503–2.311 | 0.846 | 1.210 | 0.895–1.636 | 0.215 | 1.008 | 0.474–2.142 | 0.984 |
| Other | 0.942 | 0.742–1.197 | 0.626 | 1.235 | 0.546–2.790 | 0.612 | 0.989 | 0.789–1.240 | 0.925 | 1.364 | 0.627–2.969 | 0.434 |
| Sex | ||||||||||||
| Male | 1 | 1 | 1 | 1 | ||||||||
| Female | 0.887 | 0.748–1.053 | 0.171 | 0.804 | 0.451–1.432 | 0.458 | 0.880 | 0.746–1.038 | 0.130 | 0.710 | 0.404–1.247 | 0.233 |
| Marital status | ||||||||||||
| Married | 1 | 1 | 1 | 1 | ||||||||
| Not married | 1.093 | 0.922–1.296 | 0.303 | 0.838 | 0.467–1.504 | 0.554 | 1.112 | 0.944–1.310 | 0.202 | 0.842 | 0.477–1.485 | 0.552 |
| Histologic grade | ||||||||||||
| Grade I + II | 1 | 1 | 1 | 1 | ||||||||
| Grade III + IV | 1.574 | 1.333–1.859 | 2.583 | 1.483–4.499 | 1.560 | 1.329–1.832 | 2.398 | 1.400–4.107 | ||||
| AJCC stage | ||||||||||||
| Stage I | 1 | 1 | 1 | 1 | ||||||||
| Stage II | 1.766 | 1.341–2.326 | 0.969 | 0.371–2.534 | 0.949 | 1.760 | 1.356–2.285 | 0.832 | 0.323–2.141 | 0.703 | ||
| Stage III | 2.176 | 1.657–2.858 | 1.837 | 0.847–3.987 | 0.124 | 2.073 | 1.597–2.691 | 1.543 | 0.729–3.267 | 0.257 | ||
| Stage IV | 2.397 | 1.846–3.113 | 1.971 | 0.864–4.496 | 0.107 | 2.315 | 1.804–2.971 | 2.018 | 0.909–4.478 | 0.084 | ||
| Surgery performed | ||||||||||||
| Performed | 1 | 1 | 1 | 1 | ||||||||
| Not performed | 4.115 | 3.321–5.098 | 2.897 | 1.424–5.891 | 3.938 | 3.210–4.830 | 2.784 | 1.392–5.569 | ||||
Abbreviations: AJCC, American Joint Committee on Cancer; MF, mass-forming; PI, periductal infiltrating.
a Bold type indicates statistical significance.
Figure 2Kaplan–Meier curves of cancer-specific survival (CSS, A) and overall survival (OS, B) based on the AJCC stage of the mass-forming type (MF-type) of intrahepatic cholangiocarcinoma.
Figure 3Kaplan–Meier curves of cancer-specific survival (CSS, A) and overall survival (OS, B) based on the AJCC stage of the periductal infiltrating type (PI-type) of intrahepatic cholangiocarcinoma.
Comparison of cancer-specific survival and overall survival between the MF-type and PI-type of intrahepatic cholangiocarcinoma after subgroup analyses using a multivariate Cox proportional hazard model
| AJCC stage (8th edition, 2017) | Cancer-specific survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | pa | HR | 95% CI | pa | |
| stage I | ||||||
| MF-type ( | 1 | 1 | ||||
| PI-type ( | 1.941 | 1.141–3.302 | 1.985 | 1.202–3.280 | ||
| stage II | ||||||
| MF-type ( | 1 | 1 | ||||
| PI-type ( | 1.188 | 0.515–2.739 | 0.687 | 1.038 | 0.452–2.383 | 0.931 |
| stage III | ||||||
| MF-type ( | 1 | 1 | ||||
| PI-type ( | 1.296 | 0.728–2.307 | 0.378 | 1.214 | 0.685–2.153 | 0.506 |
| stage IV | ||||||
| MF-type ( | 1 | 1 | ||||
| PI-type ( | 1.085 | 0.714–1.650 | 0.702 | 1.104 | 0.737–1.652 | 0.632 |
| MF of stage II vs. PI of stage I | ||||||
| stage II MF-type ( | 1 | 1 | ||||
| stage I PI-type ( | 1.208 | 0.719–2.031 | 0.475 | 1.206 | 0.737–1.972 | 0.456 |
Abbreviations: AJCC, American Joint Committee on Cancer; MF, mass–forming; PI, periductal infiltrating.
aThe P value was adjusted using a multivariate Cox proportional hazard regression model that accounted for age, race, sex, marital status, histologic grade, and surgery status. Bold type indicates statistical significance.
The corresponding stage definitions for intrahepatic cholangiocarcinoma from the AJCC 6th edition (2004) and AJCC 7th edition (2010) and AJCC 8th edition (2017)
| AJCC staging classification | ||
|---|---|---|
| 8th edition (2017) | 7th edition (2010) | 6th edition (2004) |
| I | I | I |
| II | II | II+ III a |
| III | III + IV a–T4N0M0 | III b + III c |
| IV | IV b | IV |
Abbreviations: AJCC, American Joint Committee on Cancer.